Positron emission tomography has shown good diagnostic properties in prostate cancer since the publication of the first clinical trial with 68Ga-PSMA, in 2012.(11)Subsequently, the use of PET has been evaluated in different settings, including primary staging and biochemical recurrence.(18-23)Luiting et al.(24)analyzed nine retrospective and two prospective studies to determine the ability of 68Ga-PSMA PET-CT to detect pelvic lymph node metastasis in patients with prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.